结直肠癌患者血清半胱氨酸蛋白酶抑制剂C水平检测及临床意义  

Detection and clinical significance of serum cysteine protease inhibitor C level in patients with colorectal carcinoma

作　　者：李琛 李璐 罗文英 杨海霞 宏小翠 黄哲 黄先进 Li Chen;Li Lu;Luo Wenying;Yang Haixia;Hong Xiaocui;Huang Zhe;Huang Xianjin(Department of Laboratory,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China;Teaching and Research Section of Histology and Embryology,Guangdong Medical University,Zhanjiang 524023,China;Oncology Center,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China;Department of Gastrointestinal Surgery,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China)

机构地区：[1]广东医科大学附属医院检验科,湛江524001 [2]广东医科大学组织学与胚胎学教研室,湛江524023 [3]广东医科大学附属医院肿瘤中心,湛江524001 [4]广东医科大学附属医院胃肠外科,湛江524001

出　　处：《中华实验外科杂志》2021年第3期550-552,共3页Chinese Journal of Experimental Surgery

基　　金：湛江市科技攻关计划项目(2020B01335)。

摘　　要：目的探讨半胱氨酸蛋白酶抑制剂C(Cystatin C)水平在结直肠癌患者血清中的表达水平,以及比较结直肠癌患者手术前后血清Cystatin C表达水平的变化。方法收集2014年5月至2020年9月广东医科大学附属医院收治的60例结直肠癌患者和30例正常健康查体者的血清,采用颗粒增强散射免疫比浊法(PENIA)检测血清Cystatin C水平,比较40例结直肠癌患者手术前后血清Cystatin C水平,并结合临床资料进行方差分析或配对t检验统计学分析。结果结直肠癌患者血清Cystatin C水平(2.988±0.976)mg/L明显高于正常对照组(0.867±0.072)mg/L,差异有统计学意义(t=11.850、P<0.01)。Ⅳ期结直肠癌血清Cystatin C水平(4.121±0.381)mg/L明显高于Ⅲ期(3.572±0.288)mg/L、Ⅲ期明显高于Ⅱ期(2.732±0.216)mg/L、Ⅱ期明显高于Ⅰ期(1.621±0.144)mg/L、Ⅰ期明显高于正常对照组(0.867±0.072)mg/L、差异有统计学意义(t=55.336,P<0.01)。肿瘤细胞分化程度较差(黏液腺癌、印戒细胞癌、低分化腺癌)结直肠癌患者血清Cystatin水平(3.298±0.858)mg/L明显高于肿瘤细胞分化程度较好(高分化腺癌、中分化腺癌)结直肠癌患者血清Cystatin水平(2.554±0.982)mg/L,两组比较差异有统计学意义(t=3.117,P<0.05)。结直肠癌患者术后血清患者Cystatin水平(1.642±0.689)mg/L明显低于术前(2.500±0.794)mg/L,差异有统计学意义(t=33.089,P<0.01)。结论结直肠癌患者血清Cystatin C水平显著升高,Cystatin C可能在一定程度上参与结直肠癌的发生发展过程。Objective To explore the serum expression of cysteine protease inhibitor C(Cystatin C)in patients with colorectal carcinoma,and to compare the changes of serum Cystatin C in patients with colorectal carcinom pre-and post-operation.Methods Totally 60 cases of colorectal carcinoma and 30 cases of normal controls from May 2014 to September 2020 on Affiliated Hospital of Guangdong Medical University were enrolled in this study.Serum Cystatin C was measured by particle enhanced scattering immunoturbidimetric method(PENIA).The statistical analysis of variance or t test in combination with clinical data were carried out.Results The serum Cystatin C was correlated with clinical stage and histological grade of colorectal carcinoma.The serum Cystatin C level was elevated in all subgroups of patients with colorectal carcinoma[(2.988±0.976)mg/L]compared to the controls[(0.867±0.072)mg/L](t=11.850,P<0.01).The serum Cystatin C level in stageⅣ[(4.121±0.381)mg/L]was higher than that in stageⅢ[(3.572±0.288)mg/L],that in stageⅢwas higher than that in stageⅡ[(2.732±0.216)mg/L],that in stageⅡwas higher than in stageⅠ[(1.621±0.144)mg/L],and that in stageⅠwas higher than that in normal controls[(0.867±0.072)mg/L](t=55.336,P<0.01).The serum Cystatin C levels were significantly higher in the cases of mucoid carcinoma,signet-ring cell carcinoma and poorly differentiated adenocarcinoma[(3.298±0.858)mg/L]than those in the cases of well and moderately differentiated carcinoma[(2.554±0.982)mg/L](t=3.117,P<0.05).The serum Cystatin C level in colorectal carcinoma before and after operation was(2.500±0.794)and(1.642±0.689)mg/L respectively(t=33.089,P<0.01).Conclusion Serum Cystatin C levels are significantly elevated in patients with colorectal carcinoma,and serum Cystatin C may be a certain degree involved in the occurrence and development of colorectal carcinoma.

关 键 词：半胱氨酸蛋白酶抑制剂C 结直肠癌 手术治疗 

分 类 号：R735.34[医药卫生—肿瘤]